NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

RecruitingNA

Sponsor: China-Japan Friendship Hospital

Conditions: Obesity

Interventions: LSG-Semaglutide group, LSG-Mazdutide group, LSG-Tirzepatide group, LSG group

Countries: China

Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.

Eligibility overview

Sex: ALL

Age: 18 Years to 60 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Patients undergoing initial laparoscopic sleeve gastrectomy (LSG).
2. obesity:BMI ≥30 kg/m².
3. Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.
4. Age range: 18-60 years (inclusive).
5. Informed consent: Willing participation with documented consent.

Exclusion Criteria:

1. Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively.
2. Prior bariatric surgery: History of any metabolic/bariatric surgical procedure.
3. Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).
4. Non-indicated candidates: Patients not meeting standard bariatric surgery indications.
5. Significant comorbidities:

5.1Advanced hepatic/renal dysfunction (Child-Pugh C or eGFR \<30 mL/min/1.73m²). 5.2Active malignancy (except non-melanoma skin cancers). 5.3Autoimmune disorders requiring immunosuppression. 5.4Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression).

Locations (1)

Beijing, China